Identifying coronary artery disease in men with type 2 diabetes: Osteoprotegerin, pulse wave velocity, and other biomarkers of cardiovascular risk

Journal of Hypertension

Volumn 29, Issue 12, 2011, Pages 2469-2475

  Davenport, Colin ^a   Ashley, David T ^b   O'Sullivan, Eoin P ^a   Corley, Brian T ^a   Fitzgerald, Patricia ^a   Agha, Amar ^a   Thompson, Christopher J ^a   O'Gorman, Donal J ^b   Smith, Diarmuid ^a  

^a BEAUMONT HOSPITAL   (Ireland)

^b DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

Biomarker; cardiovascular disease; osteoprotegerin; pulse wavevelocity; type 2 diabetes

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCIUM; CHOLESTEROL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 6; OSTEOPROTEGERIN; TRIACYLGLYCEROL; URATE;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CALCIUM BLOOD LEVEL; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; DISEASE MARKER; HEMOGLOBIN BLOOD LEVEL; HUMAN; LARGE VESSEL ATHEROSCLEROSIS; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PULSE WAVE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 81355146589     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32834c1e95     Document Type: Article

References (27)

1. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, et al. Diabetes and cardiovascular disease: A statement for healthcare professionals from the American Heart Association. Circulation 1999; 100:1134-1146.
2. Chiariello M, Indolfi C. Silent myocardial ischemia in patients with diabetes mellitus. Circulation 1996; 93:2089-2091.
3. Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr 2010; 8:29.
4. Wang TJ. Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction. Circulation 2011; 123:551-565.
5. Collin-Osdoby P, Rothe L, Anderson F, Nelson M, Maloney W, Osdoby P. Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J. Biol Chem 2001; 276:20659-20672.
6. Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K, Nishizawa Y. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002; 106:1192-1194.
7. O'Sullivan EP, Ashley DT, Davenport C, Kelly J, Devlin N, Crowley R, et al. Osteoprotegerin is higher in peripheral arterial disease regardless of glycaemic status. Thromb Res 2010; 126:e423-e427.
8. Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B, Hofbauer LC. Increased osteoprotegerin serum levels in men with coronary artery disease. J. Clin Endocrinol Metab 2003; 88:1024-1028.
9. Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004; 109:2175-2180.
10. Ueland T, Jemtland R, Godang K, Kjekshus J, Hognestad A, Omland T, et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J. Am. Coll Cardiol 2004; 44:1970-1976.
11. Nybo M, Rasmussen LM. The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: A systematic literature review. Eur J. Endocrinol 2008; 159:603-608.
12. Reinhard H, Lajer M, Gall MA, Tarnow L, Parving HH, Rasmussen LM, Rossing P. Osteoprotegerin and mortality in type 2 diabetic patients. Diabetes Care 2010; 33:2561-2566.
13. Knudsen ST, Foss CH, Poulsen PL, Andersen NH, Morgensen CE, Rasmussen LM. Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J. Endocrinol 2003; 149:39-42.
14. Terekeci HM, Senol MG, Top C, Sahan B, Celik S, Sayan O, et al. Plasma osteoprotegerin concentrations in type 2 diabetic patients and its association with neuropathy. Exp Clin Endocrinol Diabetes 2009; 117:119-123.
15. Xiang GD, Xu L, Zhao LS, Yue L, Hou J. The relationship between plasma osteoprotegerin and endothelium-dependent arterial dilation in type 2 diabetes. Diabetes 2006; 55:2126-2131.
16. Secchiero P, Corallini F, Pandolfi A, Consoli A, Candido R, Fabris B, et al. An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am. J. Pathol 2006; 169:2236-2244.
17. O'Sullivan EP, Ashley DT, Davenport C, Devlin N, Crowley R, Agha A, et al. Osteoprotegerin and biomarkers of vascular inflammation in type 2 diabetes. Diabetes Metab Res Rev 2010; 26:496-502.
18. Oh KW, Rhee EJ, Lee WY, Kim SW, Oh Es, Baek KH, et al. The relationship between circulating osteoprotegerin levels and bone mineral metabolism in healthy women. Clin Endocrinol (Oxf) 2004; 61:244-249.
19. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al. European Network for Noninvasive Investigation of Large Arteries. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006; 27:2588-2605.
20. Hickson SS, Butlin M, Broad J, Avolio AP, Wilkinson IB, McEniery CM. Validity and repeatability of the Vicorder apparatus: A comparison with the SphygmoCor device. Hypertens Res 2009; 32:1079-1085.
21. Khoshdel AR, Carney SL, Nair BR, Gillies A. Better management of cardiovascular diseases by pulse wave velocity: combining clinical practice with clinical research using evidence-based medicine. Clin Med Res 2007; 5:45-52.
22. Ohnishi H, Saitoh S, Takagi S, Ohata J, Isobe T, Kikuchi Y, et al. Pulse wave velocity as an indicator of atherosclerosis in impaired fasting glucose: The Tanno and Sobetsu study. Diabetes Care 2003; 26:437-440.
23. Sarwar N, Thompson AJ, Di Angelantonio E. Markers of inflammation and risk of coronary heart disease. Dis Markers 2009; 26:217-225.
24. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al. Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107:499-511.
25. Nishida H, Horio T, Suzuki Y, Iwashima Y, Tokudome T, Yoshihara F, et al. Interleukin-6 as an independent predictor of future cardiovascular events in high-risk Japanese patients: comparison with C-reactive protein. Cytokine 2011; 53:342-346.
26. Wen CP, David Cheng TY, Chan Ht, Tsai MK, Chung WS, Tsai SP, et al. Is high serum uric acid a risk marker or a target for treatment? Examination of its independent effect in a large cohort with low cardiovascular risk. Am. J. Kidney Dis 2010; 56:273-288.
27. Brodov Y, Chouraqui P, Goldenberg I, Boyko V, Mandelzweig L, Behar S. Serum uric acid for risk stratification of patients with coronary artery disease. Cardiology 2009; 114:300-305.